Pyridoxine Hydrochloride
FDA-approved product (injectable, injection), marketed as Hexa-Betalin, Pyridoxine Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia
- Anemia (phenotype)
- Chronic kidney disease
- Folate deficiency
- Iron deficiency anemia
- Nausea and vomiting
- Osteoporosis
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other plain vitamin preparations
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Pyridoxine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae12.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Pyridoxine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Date Fruit Benefits to Treat Morning Sickness in First Trimester of Pregnancy
NCT07354529 · start 2025-06-15
Registered record
- Registry ID
- NCT07354529
- Conditions
- Pregnancy
- Interventions
- Date fruit; Doxylamine succinate 10 mg + Pyridoxine HCl 10 mg; Diet
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2025-06-15
- Completion
- 2026-02-01
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPregnancyInterventionDate fruit; Doxylamine succinate 10 mg + Pyridoxine HCl 10 mg; DietPhaseNot applicableRegistry statusActive not recruitingClinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
NCT06152991 · start 2023-09-25
Registered record
- Registry ID
- NCT06152991
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- GODEX; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Enrolling by invitation
- Start
- 2023-09-25
- Completion
- 2027-02-26
- Enrolment
- 196
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Alcoholic Fatty Liver DiseaseInterventionGODEX; PlaceboPhasePhase 3Registry statusEnrolling by invitationIsoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients
NCT06512831 · start 2023-06-01
Registered record
- Registry ID
- NCT06512831
- Conditions
- Kidney Transplantation; Tuberculosis; Isoniazid Toxicity
- Interventions
- Isoniazid
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-06-01
- Completion
- 2024-03-01
- Enrolment
- 1,348
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Transplantation; Tuberculosis; Isoniazid ToxicityInterventionIsoniazidPhaseNot applicableRegistry statusCompletedDoxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
NCT05473520 · start 2023-05-24
Registered record
- Registry ID
- NCT05473520
- Conditions
- Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
- Interventions
- Doxycycline; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2023-05-24
- Completion
- 2030-01-31
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)InterventionDoxycycline; PlaceboPhasePhase 3Registry statusRecruitingThe Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age
NCT05682261 · start 2023-03-23
Registered record
- Registry ID
- NCT05682261
- Conditions
- Anemia
- Interventions
- UNIMMAP-MMS; IFA; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-03-23
- Completion
- 2023-10-17
- Enrolment
- 265
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemiaInterventionUNIMMAP-MMS; IFA; PlaceboPhaseNot applicableRegistry statusCompletedTherapeutic Implications of Acutaping on Nausea and Vomiting During Pregnancy
NCT06259747 · start 2023-02-03
Registered record
- Registry ID
- NCT06259747
- Conditions
- Nausea; Vomiting of Pregnancy
- Interventions
- Acutaping; Doxylamine and Pyridoxine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-02-03
- Completion
- 2023-12-15
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNausea; Vomiting of PregnancyInterventionAcutaping; Doxylamine and PyridoxinePhaseNot applicableRegistry statusCompletedBoard Game Project for Adolescents with Tourette Syndrome
NCT05566236 · start 2022-09-20
Registered record
- Registry ID
- NCT05566236
- Conditions
- Tourette Syndrome in Adolescence; Social Adjustment; Psychosocial Functioning
- Interventions
- board game
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-09-20
- Completion
- 2024-08-01
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTourette Syndrome in Adolescence; Social Adjustment; Psychosocial FunctioningInterventionboard gamePhaseNot applicableRegistry statusCompletedSafety of Administering Isoniazid to SLE Patients to Prevent TB
NCT06618573 · start 2022-08-15
Registered record
- Registry ID
- NCT06618573
- Conditions
- Tuberculosis; Systemic Lupus Erythematosus
- Interventions
- Isoniazid/Pyridoxine; Saccharum Lactis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Recruiting
- Start
- 2022-08-15
- Completion
- 2025-12-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis; Systemic Lupus ErythematosusInterventionIsoniazid/Pyridoxine; Saccharum LactisPhasePhase 2 / Phase 3Registry statusRecruitingOne-month Latent Tuberculosis Treatment for Renal Transplant Candidates
NCT05411744 · start 2022-07-01
Registered record
- Registry ID
- NCT05411744
- Conditions
- Latent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left Kidney
- Interventions
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2022-07-01
- Completion
- 2029-06-30
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLatent Tuberculosis; End Stage Renal Disease; Renal Transplant Candidate for Right Kidney; Renal Transplant Candidate for Left KidneyIntervention1 month Rifapentine, Isoniazid and Vitamin B6PhasePhase 4Registry statusActive not recruitingEvaluation of Collagen-based Medical Device Treatment Combined With Physiotherapy in Subjects With Achilles Tendinopathy.
NCT05464498 · start 2022-06-13
Registered record
- Registry ID
- NCT05464498
- Conditions
- Tendinopathy; Insertional Achilles Tendinopathy; Achilles Tendinopathy; Peritendinitis
- Interventions
- MD-Tissue Collagen Medical Device; eccentric strengthening protocol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2022-06-13
- Completion
- 2026-11-01
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTendinopathy; Insertional Achilles Tendinopathy; Achilles Tendinopathy; PeritendinitisInterventionMD-Tissue Collagen Medical Device; eccentric strengthening protocolPhaseNot applicableRegistry statusRecruitingMicronutrient Supplement for Nurse Burnout
NCT05363410 · start 2022-05-01
Registered record
- Registry ID
- NCT05363410
- Conditions
- Burnout, Professional; Stress, Psychological
- Interventions
- MagnéVie B6®; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2022-05-01
- Completion
- 2023-04-30
- Enrolment
- 88
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBurnout, Professional; Stress, PsychologicalInterventionMagnéVie B6®; PlaceboPhaseNot applicableRegistry statusUnknownEvaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo
NCT05221892 · start 2021-11-22
Registered record
- Registry ID
- NCT05221892
- Conditions
- Vertigo
- Interventions
- Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin; Ginger
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-11-22
- Completion
- 2023-03-31
- Enrolment
- 334
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVertigoInterventionGamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin; GingerPhasePhase 4Registry statusCompletedEvaluation of PDE MAX
NCT04672226 · start 2021-06-01
Registered record
- Registry ID
- NCT04672226
- Conditions
- Pyridoxine Dependant Epilepsy
- Interventions
- PDE MAX
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-06-01
- Completion
- 2023-07-31
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPyridoxine Dependant EpilepsyInterventionPDE MAXPhaseNot applicableRegistry statusCompletedSumor as Adjuvant Therapy in Treatment-resistant Major Depression
NCT04832178 · start 2021-06-01
Registered record
- Registry ID
- NCT04832178
- Conditions
- Major Depressive Disorder
- Interventions
- SUMOR; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-06-01
- Completion
- 2024-06-01
- Enrolment
- 102
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionSUMOR; PlaceboPhasePhase 4Registry statusUnknownVitamin B Complex Improved Exercise Performance and Anti-fatigue
NCT05586295 · start 2021-03-03
Registered record
- Registry ID
- NCT05586295
- Conditions
- Exercise Performance; Fatigue
- Interventions
- Placebo; EX plus
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-03-03
- Completion
- 2021-06-26
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionExercise Performance; FatigueInterventionPlacebo; EX plusPhaseNot applicableRegistry statusCompleted